Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver
Authors:
Open Access
- 22 May 2015
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 62 (2) , 646-648
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trialThe Lancet, 2015
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistanceNature Medicine, 2015
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver diseaseJournal of Clinical Investigation, 2014
- FXR is a molecular target for the effects of vertical sleeve gastrectomyNature, 2014
- Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signalLiver International, 2014
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesityNature Communications, 2013
- Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasisCell Metabolism, 2005
- Regulation of SREBP Processing and Membrane Lipid Production by Phospholipids in DrosophilaScience, 2002